MAAT INDEX

CLAIM #48434 · Pfizer Inc (PFE) · 2024Q2 earnings call · Jul 30, 2024

We do not expect that the market will continue being as big, particularly for us, after we see generics entering into it.

Albert Bourla · CEO

Verdict
PENDING
Direction
down
Magnitude
Due
Jul 30, 2026
Metric
company_kpi
Intensity
expects

How to check this claim

Look at: Company's revenue from the specific product/market referenced, following generic entry

It came true if: Reported revenue from that product/market declines from pre-generic-entry level (year-over-year decrease > 0%)

Where: Company quarterly/annual revenue disclosures by product (10-Q/10-K or earnings call segment data)

Knowable after: 2026-07-30

Verify independently

SEC filings for PFE · Quote is verbatim from the 2024Q2 earnings call.